Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.
Unbelievable but it's 100% happening
Really great find.
Based on the snippets of data released I do think further FDA support is a given however, based on historic data, Avacta has an 87% likelihood of receiving Fast track. Breakthrough, accelerated approval or priority review.
So what's the value OF AVA6K when one of these doors is opened by the FDA????
There is HUGE value to big pharma
CJ,
Phase 2 is planned to be a registrational study.
Fyi, Registrational Study means a human clinical trial that is intended (as of the time the clinical trial is initiated) to obtain sufficient data and results to support the filing of an application for Drug Approval of a compound or product.
Following phase 2 completion/approval, Avacta could outsource the production to 3rd party or simply and immediately licence the tech to each Dox player.
I doubt that these options will be reality as buy out will occur prior phase 2 start.
The ability to sell off the Dx wing is an important lever for any ongoing funding negotiations.
We are not desperate and there are avenues enabling avacta to fund AVA6k all the way to final approval / revenue.
Major news.
Point had an exclusive license to 'Ground-Breaking' technology and seems Lilly have acted quickly to secure it. THey will now have sights on the bigger prize (Avacta). I wont be surprised to see other big players move quickly now.
Avacta confirmed last week that the Pre|CISION platform works! The Chairman has even stated, in a legally approved RNS statement, that the RESULTS are 'Ground-Breaking.'
"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.
Avacta has moved from not wishing to discuss the phase 1a data until completion of the study, to publicly stating that the results are ground-breaking - yet you can still buy today at the same MC as was prior to first patient dose!!!
You can be 100% sure that when Avacta release the detailed data (could be anytime now) it is going to blow the market away. There is no way the Chair makes such a comment in an RNS weeks prior to data release, if said data is not absolutely blockbuster.
I dont think there has ever been such a huge disconnect between market value and asset value.